Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 4, 2011, Pages 374-377

  Bunck, M C ^a   Eliasson, B ^b   Corner A ^c,d   Heine, R J ^a,e   Shaginian, R M ^e   Taskinen, M R ^c   Yki Jarvinen H ^c   Smith, U ^b   Diamant, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse drug reactions; Incretin therapy; Randomized trial

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; EXENDIN 4; INSULIN GLARGINE; PHOSPHATE;

ALKALINE PHOSPHATASE BLOOD LEVEL; BODY WEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPOGLYCEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

EID: 79951870602     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01355.x     Document Type: Letter

References (10)

1. Khazai NB, Beck GR Jr, Umpierrez GE. Diabetes and fractures: an overshadowed association. Curr Opin Endocrinol Diabetes Obes 2009; 16: 435-445.
2. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48: 1292-1299.
3. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
4. Jensen LB, Kollerup G, Quaade F et al. Bone mineral changes in obese women during a moderate weight loss with and without calcium supplementation. J Bone Miner Res 2001; 16: 141-147.
5. Riedt CS, Cifuentes M, Stahl T et al. Overweight postmenopausal women lose bone with moderate weight reduction and 1 g/day calcium intake. J Bone Miner Res 2005; 20: 455-463.
6. Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 2005; 20: 1497-1506.
7. Nuche Berenguer B, Portal-Núnez S, Moreno P et al. Presence of a functional receotpr for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol 2010; 225: 585-592.
8. Nuche Berenguer B, Moreno P, Portal-Núnez S et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 2010; 159: 61-66.
9. Bunck MC, Diamant M, Cornér A et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-768.
10. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447.